CoChat
Sign Up
Cited by 400

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors

Grösch, Sabine, Maier, Thorsten Jürgen, Schiffmann, Susanne, Geisslinger, Gerd·2006·JNCI: Journal of the National Cancer Institute
DOI 10.1093/jnci/djj206
Open this paper in CoChat — free account

Abstract

Nonsteroidal antiinflammatory drugs (NSAIDs) appear to reduce the risk of developing cancer. One mechanism through which NSAIDs act to reduce carcinogenesis is to inhibit the activity of cyclooxygenase-2 (COX-2), an enzyme that is overexpressed in various cancer tissues. Overexpression of COX-2 increases cell proliferation and inhibits apoptosis. However, selective COX-2 inhibitors can also act through COX-independent mechanisms. In this review, we describe the COX-2-independent molecular targets of these COX-2 inhibitors and discuss how these targets may be involved in the anticarcinogenic activities of these selective COX-2 inhibitors. We also compare the concentrations of these inhibitors used in in vitro and in vivo experiments and discuss the implications of the in vitro studies for clinical management of cancer with these drugs.

Overview

Integrity signals

Registry

Crossref · 10.1093/jnci/djj206

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 175

  1. Leaper DJ, French B, Bennett A. Reduction by flurbiprofen of primary tumor growth and local metastasis formation in mice. Adv Prostaglandin Thromboxane Res1980 ; 6 : 591 –3.
  2. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol1983 ; 24 : 83 –7. · DOI
  3. Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci2003 ; 48 : 1998 –2002. · DOI
  4. Konturek PC, Konturek SJ, Bielanski W, Kania J, Zuchowicz M, Hartwich A, et al. Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients. Dig Dis Sci2003 ; 48 : 2005 –17. · DOI
  5. Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Nitert M, et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol1999 ; 470 : 45 –53. · DOI
  6. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol2003 ; 21 : 2645 –50. · DOI
  7. Crane CH, Mason K, Janjan NA, Milas L. Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am J Clin Oncol2003 ; 26 : S81 –4. · DOI
  8. Richard CS, Berk T, Bapat BV, Haber G, Cohen Z, Gallinger S. Sulindac for periampullary polyps in FAP patients. Int J Colorectal Dis1997 ; 12 : 14 –8. · DOI
  9. Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int2004 ; 93 : 275 –8. · DOI
  10. Sandler AB, Dubinett SM. COX-2 inhibition and lung cancer. Semin Oncol2004 ; 31 (2 Suppl 7): 45 –52. · DOI
  11. Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res2003 ; 37 : 1 –24. · DOI
  12. Cohen EG, Almahmeed T, Du B, Golijanin D, Boyle JO, Soslow RA, et al. Microsomal prostaglandin E synthase-1 is overexpressed in head and neck squamous cell carcinoma. Clin Cancer Res2003 ; 9 : 3425 –30.
  13. Golijanin D, Tan JY, Kazior A, Cohen EG, Russo P, Dalbagni G, et al. Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin Cancer Res2004 ; 10 : 1024 –31. · DOI
  14. Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC. Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer2001 ; 85 : 1023 –31. · DOI
  15. Jang TJ. Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer and during gastric carcinogenesis. Virchows Arch2004 ; 445 : 564 –71. · DOI
  16. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem2003 ; 278 : 19396 –405. · DOI
  17. Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ, et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res2001 ; 7 : 2669 –74.
  18. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res2001 ; 7 : 3971 –6.
  19. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer2000 ; 89 : 2637 –45. · DOI
  20. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res2001 ; 7 : 429 –34.
  21. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res1999 ; 59 : 5647 –50. · DOI
  22. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res1999 ; 59 : 991 –4.
  23. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res1999 ; 59 : 4356 –62.
  24. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res1998 ; 58 : 3761 –4.
  25. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res1999 ; 5 : 1001 –5.
  26. Khan KN, Masferrer JL, Woerner BM, Soslow R, Koki AT. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol2001 ; 36 : 865 –9. · DOI
  27. Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplasic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med1999 ; 190 : 445 –50. · DOI
  28. Chinery R, Coffey RJ, Graves-Deal R, Kirkland SC, Sanchez SC, Zackert WE, et al. Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res1999 ; 59 : 2739 –46.
  29. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci2000 ; 30 : 3 –21.
  30. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res1998 ; 58 : 362 –6.
  31. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem2001 ; 276 : 48997 –9002. · DOI
  32. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology2002 ; 35 : 552 –9. · DOI
  33. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res2002 ; 62 : 4903 –8.
  34. Kakiuchi Y, Tsuji S, Tsujii M, Murata H, Kawai N, Yasumaru M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigenson colon cancer cells and enhanced liver metastasis. Cancer Res2002 ; 62 : 1567 –72.
  35. Li G, Yang T, Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun2002 ; 299 : 886 –90. · DOI
  36. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer2000 ; 83 : 324 –8. · DOI
  37. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A1997 ; 94 : 3336 –40. · DOI · Paper page
  38. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer2001 ; 91 : 894 –9. · DOI
  39. Liu XH, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, et al. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis1999 ; 17 : 687 –94. · DOI
  40. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem2000 ; 7 : 1163 –70. · DOI
  41. Peek RM Jr. Prevention of colorectal cancer through the use of COX-2 selective inhibitors. Cancer Chemother Pharmacol2004 ; 54 Suppl 1: S50 –6. · DOI
  42. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets2004 ; 4 : 29 –42. · DOI
  43. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst2002 ; 94 : 252 –66. · DOI
  44. Chan TA. Cyclooxygenase inhibition and mechanisms of colorectal cancer prevention. Curr Cancer Drug Targets2003 ; 3 : 455 –63. · DOI
  45. Evans JF, Kargman SL. Cancer and cyclooxygenase-2 (COX-2) inhibition. Curr Pharm Des2004 ; 10 : 627 –34. · DOI
  46. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J2001 ; 15 : 2057 –72. · DOI
  47. Soh JW, Weinstein IB. Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog Exp Tumor Res2003 ; 37 : 261 –85. · DOI
  48. Simon LS. COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile? Gastroenterol Clin North Am2001 ; 30 : 1011 –25, viii. · DOI
  49. Alsalameh S, Burian M, Mahr G, Woodcock BG, Geisslinger G. The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther2003 ; 17 : 489 –501. · DOI
  50. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther2001 ; 296 : 558 –66. · DOI
  51. Goldenberg MM. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther1999 ; 21 : 1497 –513; discussion 1427–8. · DOI
  52. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA2000 ; 284 : 1247 –55. · DOI
  53. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med2000 ; 343 : 1520 –8. [ See also two pages following article.] · DOI
  54. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med2005 ; 352 : 1071 –80. · DOI
  55. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery. N Engl J Med2005 ; 352 : 1081 –91. · DOI
  56. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med2004 ; 351 : 1709 –11. · DOI
  57. Maillard M, Burnier M. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf2006 ; 5 : 83 –94. · DOI
  58. Spektor G, Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk—where are we now? Nat Clin Pract Cardiovasc Med2005 ; 2 : 290 –300. · DOI
  59. Konstantinopoulos PA, Lehmann DF. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol2005 ; 45 : 742 –50. · DOI
  60. Tegeder I, Geisslinger G. Cariovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naun Schmiedebergs Arch Pharmacol2006 ; 373 : 1 –17. · DOI
  61. Kardosh A, Blumenthal M, Wang WJ, Chen TC, Schonthal AH. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther2004 ; 3 : 55 –62. · DOI
  62. Narayanan BA, Condon MS, Bosland MC, Narayanan NK, Reddy BS. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res2003 ; 9 : 3503 –13.
  63. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J2001 ; 15 : 2742 –4. · DOI
  64. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol2004 ; 67 : 1469 –78. · DOI
  65. Han C, Leng J, Demetris AJ, Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res2004 ; 64 : 1369 –76. · DOI
  66. Lin HP, Kulp SK, Tseng PH, Yang YT, Yang CC, Chen CS. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther2004 ; 3 : 1671 –80. · DOI
  67. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res2004 ; 2 : 632 –42. · DOI
  68. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem2002 ; 277 : 27613 –21. · DOI
  69. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res2004 ; 64 : 4309 –18. · DOI
  70. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, et al. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res2004 ; 64 : 1444 –51. · DOI
  71. Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology2004 ; 39 : 1028 –37. · DOI
  72. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol2001 ; 3 : 245 –52. · DOI
  73. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol2001 ; 21 : 5644 –57. · DOI
  74. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle2003 ; 2 : 339 –45. · DOI · Paper page
  75. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med2002 ; 8 : 1153 –60. · DOI
  76. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med2002 ; 8 : 1136 –44. · DOI
  77. Brennan P, Babbage JW, Burgering BM, Groner B, Reif K, Cantrell DA. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity1997 ; 7 : 679 –89. · DOI
  78. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem1998 ; 273 : 29864 –72. · DOI
  79. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT—a major therapeutic target. Biochim Biophys Acta2004 ; 1697 : 3 –16. · DOI
  80. Kundu N, Smyth MJ, Samsel L, Fulton AM. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat2002 ; 76 : 57 –64. · DOI
  81. Ruvolo PP. Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res2003 ; 47 : 383 –92. · DOI
  82. Ostrowski J, Wocial T, Skurzak H, Bartnik W. Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors? Br J Cancer2003 ; 88 : 1143 –51. · DOI
  83. Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer2004 ; 4 : 781 –92. · DOI
  84. Wolter F, Ulrich S, Stein J. Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in colorectal cancer: key role of polyamines? J Nutr2004 ; 134 : 3219 –22. · DOI
  85. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol2004 ; 68 : 341 –50. · DOI
  86. Tseng WW, Deganutti A, Chen MN, Saxton RE, Liu CD. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg2002 ; 6 : 838 –43; discussion 844. · DOI
  87. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res2003 ; 63 : 586 –92.
  88. Gardner SH, Hawcroft G, Hull MA. Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. Br J Cancer2004 ; 91 : 153 –63. · DOI
  89. Patti R, Gumired K, Reddanna P, Sutton LN, Phillips PC, Reddy CD. Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib. Cancer Lett2002 ; 180 : 13 –21. · DOI
  90. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem2000 ; 275 : 11397 –403. · DOI
  91. Lim ML, Lum MG, Hansen TM, Roucou X, Nagley P. On the release of cytochrome c from mitochondria during cell death signaling. J Biomed Sci2002 ; 9 (6 Pt 1): 488 –506. · DOI
  92. Green DR, Evan GI. A matter of life and death. Cancer Cell2002 ; 1 : 19 –30. · DOI · Paper page
  93. Cryns V, Yuan J. Proteases to die for. Genes Dev1998 ; 12 : 1551 –70. · DOI
  94. Jendrossek V, Handrick R, Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. Faseb J2003 ; 17 : 1547 –9. · DOI
  95. Nam DH, Park K, Park C, Im YH, Kim MH, Lee S, et al. Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep2004 ; 11 : 263 –8. · DOI
  96. Wun T, McKnight H, Tuscano JM. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res2004 ; 28 : 179 –90. · DOI
  97. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer2005 ; 115 : 484 –92. · DOI
  98. Catalano A, Graciotti L, Rinaldi L, Raffaelli G, Rodilossi S, Betta P, et al. Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer2004 ; 109 : 322 –8. · DOI
  99. Kern MA, Schubert D, Sahi D, Schoneweiss MM, Moll I, Haugg AM, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology2002 ; 36 (4 Pt 1): 885 –94. · DOI
  100. Kim SH, Song SH, Kim SG, Chun KS, Lim SY, Na HK, et al. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J Cancer Res Clin Oncol2004 ; 130 : 551 –60. · DOI
  101. Qiu W, Zhou B, Zou H, Liu X, Chu PG, Lopez R, et al. Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma. Am J Pathol2004 ; 165 : 1689 –99. · DOI
  102. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst2004 ; 96 : 1769 –80. · DOI
  103. Tang C, Liu C, Zhou X, Wang C. Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Int J Cancer2004 ; 112 : 470 –4. · DOI
  104. Qadri SS, Wang JH, Redmond KC, AF OD, Aherne T, Redmond HP. The role of COX-2 inhibitors in lung cancer. Ann Thorac Surg2002 ; 74 : 1648 –52. · DOI
  105. Vona-Davis L, Riggs DR, Jackson BJ, McFadden DW. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1). J Surg Res2004 ; 119 : 143 –8. · DOI
  106. Lin CF, Chen CL, Chang WT, Jan MS, Hsu LJ, Wu RH, et al. Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramideand etoposide-induced apoptosis. J Biol Chem2004 ; 279 : 40755 –61. · DOI
  107. Gill JS, Windebank AJ. Ceramide initiates NFkappaB-mediated caspase activation in neuronal apoptosis. Neurobiol Dis2000 ; 7 : 448 –61. · DOI
  108. Gomez Del Pulgar T, Velasco G, Sanchez C, Haro A, Guzman M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J2002 ; 363 (Pt 1): 183 –8. · DOI
  109. Siskind LJ. Mitochondrial ceramide and the induction of apoptosis. J Bioenerg Biomembr2005 ; 37 : 143 –53. · DOI
  110. Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J2002 ; 366 (Pt 3): 831 –7. · DOI
  111. Wang S, El-Deiry WS. Cytochrome c: a crosslink between the mitochondria and the endoplasmic reticulum in calcium-dependent apoptosis. Cancer Biol Ther2004 ; 3 : 44 –6. · DOI
  112. Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, et al. Expression of carbonic anhydrase ix (ca ix), a hypoxia-related protein, rather than vascular-endothelial growth factor (vegf), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg2006 ; 243 : 334 –40. · DOI
  113. Zavada J, Zavadova Z, Pastorek J, Biesova Z, Jezek J, Velek J. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer2000 ; 82 : 1808 –13. · DOI
  114. Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem2004 ; 47 : 550 –7. · DOI
  115. Lankat-Buttgereit B, Gregel C, Knolle A, Hasilik A, Arnold R, Goke R. Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II. Mol Cell Endocrinol2004 ; 214 : 149 –53. · DOI
  116. Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol2001 ; 158 : 905 –19. · DOI
  117. Saarnio J, Parkkila S, Parkkila AK, Pastorekova S, Haukipuro K, Pastorek J, et al. Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. J Hepatol2001 ; 35 : 643 –9. · DOI
  118. Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, Pastorek J, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol1998 ; 153 : 279 –85. · DOI
  119. Leppilampi M, Saarnio J, Karttunen TJ, Kivela J, Pastorekova S, Pastorek J, et al. Carbonic anhydrase isozymes IX and XII in gastric tumors. World J Gastroenterol2003 ; 9 : 1398 –403. · DOI
  120. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res2003 ; 9 : 802 –11.
  121. Shureiqi I, Xu X, Chen D, Lotan R, Morris JS, Fischer SM, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. Cancer Res2001 ; 61 : 4879 –84.
  122. Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, et al. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis1999 ; 20 : 1985 –95. · DOI
  123. Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A2003 ; 100 : 9968 –73. · DOI
  124. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, et al. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res2000 ; 60 : 6846 –50.
  125. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene1999 ; 18 : 6938 –47. · DOI
  126. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene1999 ; 18 : 6910 –24. · DOI
  127. Shishodia S, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res2004 ; 64 : 5004 –12. · DOI
  128. Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, et al. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB. FASEB J2001 ; 15 : 1622 –4. · DOI
  129. Niederberger E, Tegeder I, Schafer C, Seegel M, Grosch S, Geisslinger G. Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation. J Pharmacol Exp Ther2003 ; 304 : 1153 –60. · DOI
  130. Kazanov D, Dvory-Sobol H, Pick M, Liberman E, Strier L, Choen-Noyman E, et al. Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. Clin Cancer Res2004 ; 10 (1 Pt 1): 267 –71. · DOI
  131. Kusunoki N, Yamazaki R, Kawai S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum2002 ; 46 : 3159 –67. · DOI
  132. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res2002 ; 62 : 2029 –33.
  133. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol2004 ; 31 (2 Suppl 7): 2 –11. · DOI
  134. Thyss R, Virolle V, Imbert V, Peyron JF, Aberdam D, Virolle T. NF-kappaB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death. EMBO J2005 ; 24 : 128 –37. · DOI
  135. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol2002 ; 193 : 287 –92. · DOI
  136. Khachigian LM. Early growth response-1: blocking angiogenesis by shooting the messenger. Cell Cycle2004 ; 3 : 10 –1. · DOI
  137. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res2004 ; 64 : 2030 –8. · DOI
  138. Pages G, Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene—a concert of activating factors. Cardiovasc Res2005 ; 65 : 564 –73. · DOI
  139. Woods JM, Mogollon A, Amin MA, Martinez RJ, Koch AE. The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol2003 ; 74 : 282 –90. · DOI
  140. Peluffo GD, Stillitani I, Rodriguez VA, Diament MJ, Klein SM. Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. Int J Cancer2004 ; 110 : 825 –30. · DOI
  141. Cha HS, Ahn KS, Jeon CH, Kim J, Koh EM. Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes. Rheumatol Int2004 ; 24 : 207 –11. · DOI
  142. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J1999 ; 13 : 781 –92. · DOI
  143. Lee HC, Park IC, Park MJ, An S, Woo SH, Jin HO, et al. Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2. J Cell Biochem2005 ; 94 : 597 –610. · DOI
  144. Kolligs FT, Bommer G, Goke B. Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion2002 ; 66 : 131 –44. · DOI
  145. Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J. Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer2001 ; 30 : 316 –21. · DOI
  146. Rask K, Nilsson A, Brannstrom M, Carlsson P, Hellberg P, Janson PO, et al. Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta. Br J Cancer2003 ; 89 : 1298 –304. · DOI
  147. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med2000 ; 342 : 1946 –52. · DOI
  148. Maier TJ, Janssen A, Schmidt R, Geisslinger G, Grosch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J2005 ; 19 : 1353 –5. · DOI
  149. Fukumoto S, Hsieh CM, Maemura K, Layne MD, Yet SF, Lee KH, et al. Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem2001 ; 276 : 17479 –83. · DOI
  150. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science1998 ; 281 : 1509 –12. · DOI · Paper page
  151. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature1999 ; 398 : 422 –6. · DOI · Paper page
  152. Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, Garrett E, et al. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res2003 ; 63 : 3145 –53.
  153. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene1999 ; 18 : 2883 –91. · DOI
  154. Gustavson MD, Crawford HC, Fingleton B, Matrisian LM. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters. Mol Carcinog2004 ; 41 : 125 –39. · DOI
  155. Tegeder I, Niederberger E, Israr E, Guhring H, Brune K, Euchenhofer C, et al. Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. FASEB J2001 ; 15 : 595 –7. · DOI
  156. Grosch S, Tegeder I, Schilling K, Maier TJ, Niederberger E, Geisslinger G. Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers. FASEB J2003 ; 17 : 1316 –8. · DOI
  157. Grosch S, Schilling K, Janssen A, Maier TJ, Niederberger E, Geisslinger G. Induction of apoptosis by R-flurbiprofen in human colon carcinoma cells: involvement of p53. Biochem Pharmacol2005 ; 69 : 831 –9. · DOI
  158. Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res2001 ; 61 : 1733 –40.
  159. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res2005 ; 11 : 1999 –2007. · DOI
  160. Liu WM, Joel SP. The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration. Cancer Chemother Pharmacol2003 ; 51 : 291 –6. · DOI
  161. Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst2003 ; 95 : 1440 –52. · DOI
  162. Chow LW, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol2003 ; 86 : 443 –7. · DOI
  163. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer2005 ; 103 : 329 –38. · DOI
  164. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer2005 ; 113 : 490 –8. · DOI
  165. Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer2004 ; 101 : 133 –8. · DOI
  166. Ducreux M, Kohne CH, Schwartz GK, Vanhoefer U. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. Ann Oncol2003 ; 14 Suppl 2:ii 17 –23. · DOI
  167. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res2004 ; 10 (12 Pt 1): 4062 –7. · DOI
  168. Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, et al. The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. Cancer J2005 ; 11 : 209 –16. · DOI
  169. Pan CX, Loehrer P, Seitz D, Helft P, Juliar B, Ansari R, et al. A Phase II Trial of Irinotecan, 5-Fluorouracil and Leucovorin Combined with Celecoxib and Glutamine as First-Line Therapy for Advanced Colorectal Cancer. Oncology2005 ; 69 : 63 –70. · DOI
  170. Vogt T, Hafner C, Bross K, Bataille F, Jauch KW, Berand A, et al. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer2003 ; 98 : 2251 –6. · DOI
  171. Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol2003 ; 52 : 377 –82. · DOI
  172. Reichle A, Bross K, Vogt T, Bataille F, Wild P, Berand A, et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer2004 ; 101 : 2247 –56. · DOI
  173. Becerra CR, Frenkel EP, Ashfaq R, Gaynor RB. Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. Int J Cancer2003 ; 105 : 868 –72. · DOI
  174. Ding H, Han C, Zhu J, Chen CS, D'Ambrosio SM. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer2005 ; 113 : 803 –10. · DOI
  175. Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, et al. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst2002 ; 94 : 1745 –57. · DOI

Cited by

Sorted by citations

See all 400

Metadata

Authors
Grösch, S., Maier, T. J., Schiffmann, S., & Geisslinger, G.
Venue
JNCI: Journal of the National Cancer Institute
Publisher
Oxford University Press (OUP)
Published
2006-06-07
Volume
98
Issue
11
Pages
736-747
ISSN
  • 1460-2105
  • 0027-8874
DOI
10.1093/jnci/djj206
Cited by
400
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. https://app.cochat.ai/papers/10.1093/jnci/djj206
The paper
Grösch, S., Maier, T. J., Schiffmann, S., & Geisslinger, G. (2006). Cyclooxygenase-2 (COX-2)–Independent Anticarcinogenic Effects of Selective COX-2 Inhibitors. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djj206